Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1990-5-31
|
| pubmed:abstractText |
We examined the ability of in vitro addition of Interleukin-2 (IL-2) to differentially enhance antibody-dependent cell mediated cytotoxicity (ADCC) utilizing cultured Epstein-Barr virus infected cells and gammaglobulin (Sandoglobulin). We found significant enhancement of ADCC when IL-2 was added. Chronic Epstein-Barr virus or Chronic Fatigue Syndrome patients in a therapeutic gammaglobulin program may benefit from IL-2 given in vivo.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0141-2760
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
29
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
109-10
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:2561291-Antibody-Dependent Cell Cytotoxicity,
pubmed-meshheading:2561291-Cell Line, Transformed,
pubmed-meshheading:2561291-Cell Transformation, Viral,
pubmed-meshheading:2561291-Herpesvirus 4, Human,
pubmed-meshheading:2561291-Humans,
pubmed-meshheading:2561291-Immunoglobulin G,
pubmed-meshheading:2561291-Immunoglobulins, Intravenous,
pubmed-meshheading:2561291-Interleukin-2
|
| pubmed:year |
1989
|
| pubmed:articleTitle |
Immunotherapy and enhanced antibody-dependent cell-mediated cytotoxicity using virally-infected target cells.
|
| pubmed:affiliation |
Biological Products Branch, Centers for Disease Control, Atlanta, GA 30333.
|
| pubmed:publicationType |
Journal Article
|